EGFR and lung carcinoma: introduced erlotinib, an EGFR inhibitor commonly used in lung cancer treatment, into organoids culture and observed a significant enrichment of at least one known therapy-resistant mutation (BRAFV600E, KRASG12D, KRASG12V, and PIK3CAH1047R) associated with erlotinib after prolonged culture (69).